Short answer
Adicet Bio Inc (ACET) filed its Q1 2018 10-Q quarterly report on May 10, 2018 for the quarter ended Mar 31, 2018.
Adicet Bio Inc Q1 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales generated
- Net loss $9.9M vs $3.4M YoY, operating expenses $10.2M vs $3.4M
- R&D $8.1M, up from $3.3M, including $5.8M clinical-trial costs
- Cash $135.7M, operating cash use $7.3M vs $0.3M, IPO financing $89.9M
- Outlook: cash expected to fund operations through 2020, additional financing required, Phase 2b data expected second half 2018
Risk Factors
- No material changes to risk factors from the December 31, 2017 Form 10-K
- Carried-forward business risk: unknown or currently immaterial risks could materially harm operations
- Carried-forward financial risk: risks could materially affect financial condition
- Carried-forward performance risk: risks could materially affect future results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adicet Bio Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.